JP2001511183A5 - - Google Patents

Download PDF

Info

Publication number
JP2001511183A5
JP2001511183A5 JP1998534880A JP53488098A JP2001511183A5 JP 2001511183 A5 JP2001511183 A5 JP 2001511183A5 JP 1998534880 A JP1998534880 A JP 1998534880A JP 53488098 A JP53488098 A JP 53488098A JP 2001511183 A5 JP2001511183 A5 JP 2001511183A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998534880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001511183A (ja
Filing date
Publication date
Priority claimed from US08/796,316 external-priority patent/US5830464A/en
Application filed filed Critical
Publication of JP2001511183A publication Critical patent/JP2001511183A/ja
Publication of JP2001511183A5 publication Critical patent/JP2001511183A5/ja
Withdrawn legal-status Critical Current

Links

JP53488098A 1997-02-07 1998-02-03 癌または感染症の予防／治療のための熱ショック／ストレスタンパク質−ペプチド複合体を用いた養子免疫療法 Withdrawn JP2001511183A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/796,316 US5830464A (en) 1997-02-07 1997-02-07 Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US08/796,316 1997-02-07
PCT/US1998/002194 WO1998034642A1 (en) 1997-02-07 1998-02-03 Adoptive immunotherapy utilizing heat shock/stress protein-peptide complexes for prevention/treatment of cancer or infectious diseases

Publications (2)

Publication Number Publication Date
JP2001511183A JP2001511183A (ja) 2001-08-07
JP2001511183A5 true JP2001511183A5 (https=) 2005-10-06

Family

ID=25167900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53488098A Withdrawn JP2001511183A (ja) 1997-02-07 1998-02-03 癌または感染症の予防／治療のための熱ショック／ストレスタンパク質−ペプチド複合体を用いた養子免疫療法

Country Status (6)

Country Link
US (2) US5830464A (https=)
EP (1) EP1001807A4 (https=)
JP (1) JP2001511183A (https=)
AU (1) AU742986B2 (https=)
CA (1) CA2280945A1 (https=)
WO (1) WO1998034642A1 (https=)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6455493B1 (en) 1996-09-20 2002-09-24 University Of New Mexico Methods for using heat shock proteins
IN183280B (https=) 1996-09-20 1999-10-30 Univ New Mexico
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
KR20060111731A (ko) * 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 사람 유두종 바이러스 항원과 스트레스 단백질을 포함하는융합 단백질을 포함하는 조성물에 의해 유도된 사람 유두종바이러스 항원에 대한 면역 반응
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
JP4768122B2 (ja) * 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
WO1999048914A1 (en) * 1998-03-26 1999-09-30 The University Of New Mexico Methods for using heat shock proteins
WO1999050278A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
WO2001040292A1 (en) * 1998-11-27 2001-06-07 Novopharm Biotech Inc. Antigen-binding fragments specific for tumor associated antigens
US20040166527A1 (en) * 1999-03-30 2004-08-26 Beaudry Gary A. Compositions and methods for the identification of lung tumor cells
US6495360B1 (en) 1999-05-28 2002-12-17 Photogen, Inc. Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins
CA2378097A1 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
GB9919733D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
US7378096B2 (en) * 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
WO2001078772A1 (en) * 2000-04-17 2001-10-25 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
DE10033245A1 (de) * 2000-07-10 2002-01-24 Singh Jasuja Harpreet Verwendungen des Hitzeschockproteins gp96
EP1363938B1 (en) * 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
CA2422867A1 (en) * 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) * 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
WO2002057795A2 (en) * 2001-01-19 2002-07-25 Cambridge Scientific, Inc. Methods of diagnosis and treatment of osteoporosis
US6921534B2 (en) 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
US20040043419A1 (en) * 2001-04-17 2004-03-04 Rothman James E. Javelinization of protein antigens to heat shock proteins
HK1079705A1 (zh) * 2001-08-20 2006-04-13 University Of Connecticut Health Center 包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
EP1551957A4 (en) * 2001-10-01 2007-01-24 Univ Duke ISOLATED POLYPEPTIDE OF THE GRP94 LIGANDEN BINDING DOMAIN AND NUCLEIC ACID, CRYSTALLINE FORM THEREOF, CODING THEREOF, AND SCRAPPING METHOD WHERE IT IS USED
US7048756B2 (en) * 2002-01-18 2006-05-23 Apasara Medical Corporation System, method and apparatus for evaluating tissue temperature
US6850804B2 (en) * 2002-01-18 2005-02-01 Calfacior Corporation System method and apparatus for localized heating of tissue
US6993394B2 (en) 2002-01-18 2006-01-31 Calfacion Corporation System method and apparatus for localized heating of tissue
ES2526822T3 (es) 2002-01-31 2015-01-15 Andromeda Bio Tech Ltd. Péptidos hsp y análogos para la modulación de respuestas inmunes mediante células presentadoras de antígeno
US20050221421A1 (en) * 2002-02-08 2005-10-06 Tran Jean-Luc V Method of producing and using heat shock proteins
WO2003068941A2 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US8088569B2 (en) * 2002-03-01 2012-01-03 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003092624A2 (en) * 2002-05-02 2003-11-13 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
CA2501577A1 (en) * 2002-10-07 2004-04-22 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
RU2324493C2 (ru) * 2003-02-20 2008-05-20 Юниверсити Оф Коннектикут Хелт Сентер Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
JP5623004B2 (ja) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
WO2007050978A2 (en) * 2005-10-29 2007-05-03 University Of Connecticut Methods for the elimination of pathogens and other particulate agents
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR20110017356A (ko) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
EP2374813A1 (en) 2008-12-03 2011-10-12 Proyecto de Biomedicina Cima, S.L. Use of phenol-soluble modulins for vaccine development
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1989012455A1 (en) * 1988-06-15 1989-12-28 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) * 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
GB9200949D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
DE69333110T2 (de) * 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
FR2688227A1 (fr) * 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2130089A1 (en) * 1992-03-09 1993-09-16 Aldo Mancini Protein compound, coding nucleotide sequences, producing cell line and uses thereof
EP0636248A4 (en) * 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
WO1996013275A1 (en) * 1994-10-31 1996-05-09 Tkb Associates Limited Partnership Methods and products for enhancing immune responses
WO1997006821A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
DE19602985A1 (de) * 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
WO1997026910A2 (de) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren

Similar Documents

Publication Publication Date Title
JP2000509912A5 (https=)
JP2000509637A5 (https=)
JP2000509635A5 (https=)
JP2002504230A5 (https=)
JP2001511032A5 (https=)
JP2001511773A5 (https=)
JP2001511183A5 (https=)
JP2001511255A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2001525894A5 (https=)
JP2002511046A5 (https=)
JP2000508866A5 (https=)
JP2000508022A5 (https=)
JP2000511460A5 (https=)
JP2000508841A5 (https=)
JP2000508680A5 (https=)
JP2002511192A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2000510247A5 (https=)
JP2000510969A5 (https=)
JP2000508102A5 (https=)